R-CHOP protocol: Clinical Trials

23 trials of R-CHOP protocol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 active not recruiting, 5 completed, 5 unknown, 3 recruiting. 23 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 223Active not recruiting 7, Completed 5, Unknown 5, Recruiting 3, Not yet recruiting 2, Withdrawn 1
Phase 16Active not recruiting 3, Unknown 2, Not yet recruiting 1

Follow R-CHOP protocol: new trials by email Literature Review of R-CHOP protocol trials Research Report on R-CHOP protocol

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Celecoxib Combined with R-CHOP, R-CHOP - Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive
Phase 2RecruitingSun Yat-sen University602026-03-062026-07-22
Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study
R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL)
Phase 1 / Phase 2Not yet recruitingSun Yat-sen University1222026-02-282026-02-10
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
ZCR-CHOP, R-CHOP - BTK Inhibitors, Histone Deacetylase Inhibitor
Phase 2Not yet recruitingLi Zhiming1282025-06-012025-03-24
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)
Orelabrutinib Oral Tablet, R-CHOP Protocol - Diffuse Large B Cell Lymphoma (DLBCL)
Phase 2RecruitingSun Yat-sen University392024-11-012024-10-22
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Selinexor Oral Tablet [Xpovio], R-CHOP Protocol - Diffuse Large B Cell Lymphoma
Phase 2RecruitingSun Yat-sen University422024-08-012026-02-12
Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
Phase 1 / Phase 2UnknownSun Yat-sen University542022-11-012023-12-14
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
R-CHOP, R-CHOP + acalabrutinib - Diffuse Large B Cell Lymphoma
Phase 2Active not recruitingUniversity Hospital Southampton NHS Foundation Trust4532021-10-192026-04-30
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
Acalabrutinib, R-CHOP chemotherapy - Mantle Cell Lymphoma
Phase 2Active not recruitingUniversity Health Network, Toronto1052021-03-012026-06-12
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2Active not recruitingIncyte Biosciences Japan GK722020-12-152026-10-21
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab5432020-11-032026-11-03
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab782020-08-202026-11-04
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL
Copanlisib, R-CHOP Chemotherapy - Diffuse Large B Cell Lymphoma
Phase 2CompletedUniversity Hospital Muenster622020-06-192026-07-30
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Phase 1 / Phase 2UnknownHuiqiang Huang1402020-04-242022-04-14
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
Pembrolizumab, R-CHOP Protocol - B Cell Lymphoma, Lymphoma
Phase 2Active not recruitingUniversity of Chicago512019-08-292025-06-08
A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome
Venetoclax, DA-EPOCH-R, R-CHOP - Richter Syndrome
Phase 2Active not recruitingDana-Farber Cancer Institute692017-03-082026-07-10
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
R-CHOP - Diffuse Large B-cell Lymphoma, HIV
Phase 2CompletedUNC Lineberger Comprehensive Cancer Center392016-03-012022-10-28
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC) - Mantle Cell Lymphoma, Untreated
Phase 2CompletedMemorial Sloan Kettering Cancer Center492015-12-142024-08-30
Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Duvelisib, Rituximab, R-CHOP - Lymphoma
Phase 2WithdrawnSecuraBio2015-12-012021-03-17
Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL
R-CHOP - Diffuse Large B-cell Lymphoma
Phase 2UnknownFudan University1962013-02-012013-03-05
Erythropoietin for Management of Anemia Caused by Chemotherapy
Darbepoetin alfa, R-CHOP - Diffuse Large B-cell Lymphoma
Phase 2CompletedKosin University Gospel Hospital532012-09-012020-02-20

Showing 20 of 23. Sign in to see all of them.

Conditions studied

Lymphoma, Large B-Cell, Diffuse (16)  ·  Lymphoma (4)  ·  Lymphoma, Mantle-Cell (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Lymphoma, Follicular (2)  ·  Pyloric Stenosis, Hypertrophic (2)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, B-Cell, Marginal Zone (1)

Sponsors

Sun Yat-sen University (5)  ·  Genmab (2)  ·  CTI BioPharma (1)  ·  Dana-Farber Cancer Institute (1)  ·  Fudan University (1)  ·  Heidelberg University (1)  ·  Huiqiang Huang (1)  ·  Incyte Biosciences Japan GK (1)  ·  Kosin University Gospel Hospital (1)  ·  Li Zhiming (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Pusan National University Hospital (1)  ·  SecuraBio (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)  ·  University Health Network, Toronto (1)

Countries

China (8)  ·  United States (6)  ·  Germany (3)  ·  Canada (2)  ·  France (2)  ·  Italy (2)  ·  Japan (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Finland (1)  ·  Malawi (1)  ·  Netherlands (1)

Top investigators

Andrew Davies (1)  ·  Anita Kumar, MD (1)  ·  Anthony D. Ho, Ph.D., Prof. (1)  ·  Gabor Jurida, M.D. (1)  ·  Hagop Youssoufian, MD (1)  ·  Ho-Jin Ho-Jin (1)  ·  Justin Kline, MD (1)  ·  Matthew Painschab, MD (1)  ·  Matthew S. Davids, MD, MMSc (1)  ·  Prof. Georg Lenz, MD (1)  ·  QingQing Cai, MD. PhD. (1)  ·  Rong Tao, MD. (1)  ·  Ye Guo, MD (1)  ·  Yi Xia, MD. PhD. (1)  ·  Zhiming Li, M.D. (1)

Results publications

PMID 23946328, PMID 34022150, PMID 34788401, PMID 35418080, PMID 39792928, PMID 40632620, PMID 40920572, PMID 41563911, PMID 41784015, PMID 42411504, PMID 42541678, PMID 42622258, PMID 42660129

NIH funding

2015 (1), 2023 (1), K01TW009488 (1), R21CA180815 (1)